Details : Includes primary (osteosarcoma) and metastatic bone cancers. 

Research Status : GcMAF (Gc protein-derived macrophage activating factor) in the treatment of bone cancer : 

Immune System Activation : GcMAF activates macrophages, which are crucial for attacking and destroying cancer cells. 

Inhibition of Angiogenesis : It is shown to prevent the formation of new blood vessels that tumors need to grow. 

Reduction of Tumor Size : Studies suggest GcMAF shrink tumors by enhancing the body’s natural defenses. 

Improved Survival Rates : Preliminary research indicates that GcMAF improves survival rates by slowing cancer progression as a minimum. 

Enhanced Phagocytosis : GcMAF boosts the ability of macrophages to engulf and digest cancer cells. 

Reduction of Metastasis : It helps in reducing the spread of cancer to other parts of the body. 

Improved Quality of Life : Patients experience better overall health and reduced symptoms, leadingto a much improved quality of life. 

Synergistic Effects : GcMAF can potentially enhance the effectiveness of other cancer treatments. 

Minimal Side Effects : Compared to conventional treatments, GcMAF has no severe side effects to date.  

Restoration of Immune Function : Gcmaf helps restore the immune system’s ability to fight cancer by counteracting the effects of nagalase, an enzyme that cancer cells produce to evade immune detection.  The above is for research purposes, its is not medical advice. 

Author or bone cancer and Gcmaf : Maryjayne Aria  

#GCMAF #gcmafmaryjaynearia #gcmaf #maryjaynearia #bonecancertreatment #bonecancer